Health Care Technology(BK4167),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4167 Health Care Technology

Not Yet Opened 03-18 16:00:00 EDT

2,549.96

-30.29

-1.17%

High2,580.12	Low2,537.29	Vol44.83M
Open2,580.12	D1 Closing2,580.26	Amplitude1.66%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O571.61M	T/O Rate--	Tradable Shares0.00
P/B2.68814	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4167","market":"US","secType":"PLATE","nameCN":"Health Care Technology","latestPrice":2549.9634,"timestamp":1773863999999,"preClose":2580.257,"halted":0,"volume":44827442,"delay":0,"changeRate":-0.011741,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-30.293701,"latestTime":"03-18 16:00:00 EDT","open":2580.1172,"high":2580.1199,"low":2537.2915,"amount":571609272.323346,"amplitude":0.016598,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773907200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.68814,"peRate":-81.247546,"turnoverRate":0.030476,"increases":8,"decrements":25,"flats":0,"marketCap":49011599073.5,"floatMarketCap":40066639839.5},"requestUrl":"/m/hq/s/BK4167/tweets","defaultTab":"tweets","newsList":[{"id":"2620218510","title":"Heartflow Inc : JP Morgan Cuts Target Price to $35 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2620218510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620218510?lang=en_us&edition=fundamental","pubTime":"2026-03-19 11:26","pubTimestamp":1773890801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4060ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","HTFL"],"gpt_icon":0},{"id":"2620350260","title":"GoodRx appoints KPMG as auditor and dismisses PwC for fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620350260","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620350260?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:00","pubTimestamp":1773867610,"startTime":"0","endTime":"0","summary":"GoodRx appointed KPMG as its independent registered public accounting firm for the fiscal year ending December 31, 2026, and dismissed PwC. PwC’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinion or disclaimer and were not qualified or modified. GoodRx reported no disagreements with PwC on accounting principles or practices, financial statement disclosure, or audit scope or procedure through March 14, 2026. The company also reported no reportable events involving PwC during that period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GoodRx Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5jch7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDRX","BK4167"],"gpt_icon":0},{"id":"2620267072","title":"Aclarion FY 2025 net loss was USD 7.23 million as sales and marketing expenses nearly doubled to USD 1.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620267072","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620267072?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:58","pubTimestamp":1773867531,"startTime":"0","endTime":"0","summary":"Aclarion published its annual report on Form 10-K for FY 2025. Revenue rose 65.6% to USD 75,730, driven primarily by growing Nociscan report volumes in the UK following local coverage decisions. Sales and marketing expense more than doubled to USD 1.9 million, reflecting higher post-clearance clinical services tied to the CLARITY Trial and increased product marketing consulting. Net loss was USD 7.23 million. The company said it had USD 12.04 million in cash and cash equivalents and restricted cash as of Dec. 31, 2025, and expects current cash to fund operations into the first quarter of 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL78c0w8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2620926267","title":"LifeMD appoints Atul Kavthekar CFO and names Chris Pisano CMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620926267","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620926267?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:18","pubTimestamp":1773865089,"startTime":"0","endTime":"0","summary":"LifeMD appointed Atul Kavthekar as chief financial officer, replacing Marc Benathen, who will remain with the company through March 31, 2026. Kavthekar is a healthcare finance executive with nearly three decades of experience across provider-side healthcare, retail and specialty pharmacy, e-commerce, and technology. The company also named Chris Pisano as chief marketing officer; he has more than 25 years of marketing experience across healthcare, financial services, technology, e-commerce, and professional services and previously founded a marketing and technology venture. Jessica Friedeman, who joined in January 2023 as chief marketing officer, was appointed chief business officer and will lead enterprise and employer health offerings while continuing as general manager of the women’s health division.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3kgCcB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","LFMD","BK4183"],"gpt_icon":0},{"id":"2620264197","title":"Heartflow Q4 revenue rose 40% to USD 49.13 million as net loss narrowed to USD 24.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264197","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264197?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:01","pubTimestamp":1773864091,"startTime":"0","endTime":"0","summary":"Heartflow published a quarterly and annual earnings press release reporting fourth-quarter and full-year 2025 results. Q4 revenue rose 40% to USD 49.13 million, while gross margin improved 4.5 percentage points to 79.5%, driven mainly by higher U.S. FFRCT volume and improved production productivity from AI efficiency initiatives. Q4 net loss was USD 24.4 million and adjusted EBITDA was USD -11.12 million. For FY 2025, revenue increased 40% to USD 176.03 million and net loss was USD 116.79 million. Heartflow forecast 2026 revenue of USD 218 million to USD 222 million and non-GAAP gross margin of 80% to 81%, and CEO John Farquhar said adoption of the Heartflow Platform and scaling account activations supported results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6n4h11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","HTFL","LU0314104364.USD","IE00BN0W2T93.GBP","NDAQ","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","BK4167","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD"],"gpt_icon":0},{"id":"2620623142","title":"Heartflow Inc - 2026 Guidance: Total Revenue $218 Mln-$222 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2620623142","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620623142?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:01","pubTimestamp":1773864061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUABNZY0T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","HTFL"],"gpt_icon":0},{"id":"2620544262","title":"Heartflow Inc - Q4 2025 Total Revenue $49.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2620544262","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620544262?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:01","pubTimestamp":1773864061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUABNZY0T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","HTFL"],"gpt_icon":0},{"id":"2620126414","title":"Press Release: Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620126414","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620126414?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:01","pubTimestamp":1773864060,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., March 18, 2026  -- Heartflow, Inc.  , the leader in AI technology for coronary artery disease , today reported financial results for the fourth quarter and full year ended December 31, 2025.-- Total revenue of $49.1 million, a 40% increase year-over-year. -- Gross margin of 79.5%, non-GAAP gross margin of 79.9%. -- Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5. -- U.S. installed base of 1,465 accounts as of December 31, 2025. Total operating expenses were $56.8 million, or 116% of total revenue, compared to $42.3 million, or 121% of total revenue, in the prior year period. Non-GAAP total operating expenses were $51.7 million, or 105% of total revenue, compared to $39.9 million,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK4528","BK4588","AI","BK4551","HTFL","BK4167","AIYY","BK4023","BK4587","BK4585"],"gpt_icon":0},{"id":"2620268007","title":"HeartFlow’s NAVIGATE-PCI Registry: New Data Pathway for AI-Guided Stent Planning and HTFL Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620268007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620268007?lang=en_us&edition=fundamental","pubTime":"2026-03-19 00:32","pubTimestamp":1773851532,"startTime":"0","endTime":"0","summary":"HeartFlow, Inc. ($HTFL) announced an update on their ongoing clinical study. The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/heartflows-navigate-pci-registry-new-data-pathway-for-ai-guided-stent-planning-and-htfl-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/heartflows-navigate-pci-registry-new-data-pathway-for-ai-guided-stent-planning-and-htfl-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HTFL","ISBC","BK4167","BK4211","PCI"],"gpt_icon":0},{"id":"2620252794","title":"Nutex Health director Kelvin Spears acquires USD 944.6 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620252794","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620252794?lang=en_us&edition=fundamental","pubTime":"2026-03-18 22:41","pubTimestamp":1773844898,"startTime":"0","endTime":"0","summary":"Kelvin Spears, a director of Nutex Health, reported buying 10 common shares at USD 94.46 each. Following the purchase, Spears reported directly owning 32,137 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutex Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL94V9JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nutex Health director Kelvin Spears acquires USD 944.6 in common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUTX","BK4167","BK4196","BK4185"],"gpt_icon":0},{"id":"2620252433","title":"Doximity Initiated at Buy by Freedom Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2620252433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620252433?lang=en_us&edition=fundamental","pubTime":"2026-03-18 22:37","pubTimestamp":1773844620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DOCS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 10:37 ET (14:37 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4539","BK4585","BK4613","BK4167","DOCS"],"gpt_icon":0},{"id":"2620251432","title":"Sophia Genetics SA director Tomer Berkovitz files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251432","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251432?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:47","pubTimestamp":1773841672,"startTime":"0","endTime":"0","summary":"Sophia Genetics reported an initial statement of beneficial ownership for Tomer Berkovitz. Tomer Berkovitz was listed as a director. The filing stated that no securities were beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2ZQdsb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4167","SOPH"],"gpt_icon":0},{"id":"2620251434","title":"Sophia Genetics Chief Legal Officer Daan van Well files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251434","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251434?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:47","pubTimestamp":1773841647,"startTime":"0","endTime":"0","summary":"Daan van Well filed an initial statement of beneficial ownership as Chief Legal Officer of Sophia Genetics. The filing reported direct beneficial ownership of 261,922 ordinary shares. It also reported share options for 671,263 ordinary shares, with exercise prices ranging from USD 3.29 to USD 18.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbMPNY1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SOPH","BK4167"],"gpt_icon":0},{"id":"2620514642","title":"Sophia Genetics SA Director Didier Hirsch Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620514642","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620514642?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:47","pubTimestamp":1773841640,"startTime":"0","endTime":"0","summary":"Didier Hirsch, a director at Sophia Genetics, filed an initial statement of beneficial ownership. The filing reported 220,496 ordinary shares beneficially owned. It also reported share options covering 140,000 ordinary shares at an exercise price of USD 4.21. The filing also reported share options covering 49,751 ordinary shares at an exercise price of USD 3.04.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6r0xBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4167","SOPH"],"gpt_icon":0},{"id":"2620251455","title":"Sophia Genetics CEO Jurgi Camblong files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251455","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251455?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:47","pubTimestamp":1773841625,"startTime":"0","endTime":"0","summary":"Sophia Genetics reported an initial statement of beneficial ownership by Jurgi Camblong, its chief executive officer and a director. Camblong reported beneficial ownership of 3.31 million ordinary shares. He also reported share options covering 100,000 ordinary shares with an exercise price of USD 3.16. He also reported share options covering 1.01 million ordinary shares with an exercise price of USD 3.29.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8RZV7Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOPH","BK4539","BK4167"],"gpt_icon":0},{"id":"2620511032","title":"Sophia Genetics CSO Xu Zhenyu files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620511032","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620511032?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:46","pubTimestamp":1773841613,"startTime":"0","endTime":"0","summary":"Sophia Genetics reported an initial statement of beneficial ownership by Zhenyu Xu, Chief Scientific Officer. Xu beneficially owned 537,724 ordinary shares. Xu also reported share options covering 251,524 ordinary shares at an exercise price of USD 4.96.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7HKnnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOPH","BK4539","BK4167"],"gpt_icon":0},{"id":"2620251104","title":"Sophia Genetics CMO Philippe Menu files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251104","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251104?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:46","pubTimestamp":1773841598,"startTime":"0","endTime":"0","summary":"Sophia Genetics reported an initial statement of beneficial ownership for Philippe Menu, its chief medical officer. Menu beneficially owned 174,224 ordinary shares. He also reported share options covering 30,000 ordinary shares at a USD 4.15 exercise price. Menu reported additional share options covering 251,524 ordinary shares at a USD 4.96 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7SK5LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOPH","BK4539","BK4167"],"gpt_icon":0},{"id":"2620251462","title":"Sophia Genetics Chief People Officer Manuela Valente files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251462","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251462?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:46","pubTimestamp":1773841585,"startTime":"0","endTime":"0","summary":"Manuela Valente, Chief People Officer of SOPHiA Genetics, filed an initial statement of beneficial ownership. The filing reported 152,759 ordinary shares beneficially owned directly. It also reported share options covering 160,061 ordinary shares with an exercise price of USD 4.96. The filing also reported share options covering 119,318 ordinary shares with an exercise price of USD 3.29.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLc78kJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BK4539","SOPH"],"gpt_icon":0},{"id":"2620251108","title":"Sophia Genetics President Muken Ross files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251108","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251108?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:46","pubTimestamp":1773841585,"startTime":"0","endTime":"0","summary":"Sophia Genetics reported an initial statement of beneficial ownership filed by President Muken Ross. Ross reported indirect ownership of 200,000 ordinary shares. Ross also reported direct ownership of 273,093 ordinary shares. Ross reported share options covering 640,000 ordinary shares at a conversion or exercise price of USD 6.23. Ross also reported share options covering 503,049 ordinary shares at a conversion or exercise price of USD 4.96.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely resp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5v6MGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4167","SOPH"],"gpt_icon":0},{"id":"2620825148","title":"Sophia Genetics director Troy Cox files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825148","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825148?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:46","pubTimestamp":1773841572,"startTime":"0","endTime":"0","summary":"Troy Cox, a director of SOPHiA Genetics, filed an initial statement of beneficial ownership. The filing reported 309,019 ordinary shares held directly. It also reported share options to buy 11,500 ordinary shares at USD 4.01 per share. Additional share options covered 162,740 ordinary shares at USD 4.12 per share. Another share option covered 49,751 ordinary shares at USD 3.04 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9lBTXv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BK4539","SOPH"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4167","nameEN":"BK4167"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Health Care Technology(BK4167),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Health Care Technology(BK4167) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Health Care Technology,BK4167,Health Care Technology股票,Health Care Technology股票老虎,Health Care Technology股票老虎国际,Health Care Technology行情,Health Care Technology股票行情,Health Care Technology股价,Health Care Technology股市,Health Care Technology股票价格,Health Care Technology股票交易,Health Care Technology股票购买,Health Care Technology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Health Care Technology(BK4167),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Health Care Technology(BK4167) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}